MSB 2.17% $1.13 mesoblast limited

Management say recruitment is on track and I will take them at...

  1. 603 Posts.
    lightbulb Created with Sketch. 292
    Management say recruitment is on track and I will take them at their word. I believe the extension of the trial into Victoria is prompted by compassionate considerations and has nothing to do with any need to boost numbers. It's unfortunate it didn't happen sooner. As to the suggestion that there are insufficent takers in the US, what therapy do you think people who are stuck on ventilators (or their families) would opt for ahead of remestemsel (or the chance of being randomised to remestemcel) if given the choice? Remdesivir? Convalescent plasma? Look at the trial results for both of these and you will see that they offer the critical cases very little hope. Sure there are a few other experimental treatments about (mostly mAbs and JAK inhibitors) but these are mostly in phase 1 or 2 or are not being offered to paitents with ARDS classified as critical.


 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.13
Change
-0.025(2.17%)
Mkt cap ! $1.284B
Open High Low Value Volume
$1.15 $1.16 $1.11 $7.363M 6.488M

Buyers (Bids)

No. Vol. Price($)
5 94863 $1.13
 

Sellers (Offers)

Price($) Vol. No.
$1.13 5000 2
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.